These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 25123381)

  • 1. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir.
    Donaldson EF; Harrington PR; O'Rear JJ; Naeger LK
    Hepatology; 2015 Jan; 61(1):56-65. PubMed ID: 25123381
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resistance Analyses of Japanese Hepatitis C-Infected Patients Receiving Sofosbuvir or Ledipasvir/Sofosbuvir Containing Regimens in Phase 3 Studies.
    Mizokami M; Dvory-Sobol H; Izumi N; Nishiguchi S; Doehle B; Svarovskaia ES; De-Oertel S; Knox S; Brainard DM; Miller MD; Mo H; Sakamoto N; Takehara T; Omata M
    J Viral Hepat; 2016 Oct; 23(10):780-8. PubMed ID: 27196675
    [TBL] [Abstract][Full Text] [Related]  

  • 3. L159F and V321A Sofosbuvir-Associated Hepatitis C Virus NS5B Substitutions.
    Svarovskaia ES; Gane E; Dvory-Sobol H; Martin R; Doehle B; Hedskog C; Jacobson IM; Nelson DR; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
    J Infect Dis; 2016 Apr; 213(8):1240-7. PubMed ID: 26603202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of minor populations of NS5A and NS5B resistance-associated variants on HCV genotype-3 response to daclatasvir plus sofosbuvir, with or without ribavirin.
    McPhee F; Hernandez D; Zhou N
    Antivir Ther; 2017; 22(3):237-246. PubMed ID: 28008868
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir.
    Tong X; Le Pogam S; Li L; Haines K; Piso K; Baronas V; Yan JM; So SS; Klumpp K; Nájera I
    J Infect Dis; 2014 Mar; 209(5):668-75. PubMed ID: 24154738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prevalence of Resistance-Associated Substitutions in HCV NS5A, NS5B, or NS3 and Outcomes of Treatment With Ledipasvir and Sofosbuvir.
    Sarrazin C; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Pang PS; Chuang SM; Ma J; Ding X; Afdhal NH; Kowdley KV; Gane EJ; Lawitz E; Brainard DM; McHutchison JG; Miller MD; Mo H
    Gastroenterology; 2016 Sep; 151(3):501-512.e1. PubMed ID: 27296509
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of chronic HCV infection with DAAs in Rio de Janeiro/Brazil: SVR rates and baseline resistance analyses in NS5A and NS5B genes.
    Costa VD; Brandão-Mello CE; Nunes EP; Dos Santos Silva PGC; de Souza Rodrigues LLLX; Lampe E; do Amaral Mello FC
    PLoS One; 2019; 14(5):e0216327. PubMed ID: 31063475
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of hepatitis C virus intergenotypic recombinant strains and associated virological response to sofosbuvir/ribavirin.
    Hedskog C; Doehle B; Chodavarapu K; Gontcharova V; Crespo Garcia J; De Knegt R; Drenth JP; McHutchison JG; Brainard D; Stamm LM; Miller MD; Svarovskaia E; Mo H
    Hepatology; 2015 Feb; 61(2):471-80. PubMed ID: 25099344
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Amino Acid Substitutions in Genotype 3a Hepatitis C Virus Polymerase Protein Affect Responses to Sofosbuvir.
    Wing PAC; Jones M; Cheung M; DaSilva S; Bamford C; Jason Lee WY; Aranday-Cortes E; Da Silva Filipe A; McLauchlan J; Smith D; Irving W; Cunningham M; Ansari A; Barnes E; Foster GR
    Gastroenterology; 2019 Sep; 157(3):692-704.e9. PubMed ID: 31078622
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sofosbuvir (Sovaldi) for the treatment of hepatitis C.
    Lam B; Henry L; Younossi Z
    Expert Rev Clin Pharmacol; 2014 Sep; 7(5):555-66. PubMed ID: 24918162
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Baseline resistance associated substitutions in HCV genotype 1 infected cohort treated with Simeprevir, Daclatasvir and Sofosbuvir in Brazil.
    Aguiar BF; Campos GRF; Rodrigues JPV; Marques NN; Molina BF; Bittar C; Souza FF; Martinelli ALC; Rahal P; Pereira LRL
    Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):329-339. PubMed ID: 31523019
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sofosbuvir (Sovaldi°). Active against hepatitis C virus, but evaluation is incomplete .
    Prescrire Int; 2015 Jan; 24(156):5-10. PubMed ID: 25734194
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Significance of NS5B Substitutions in Genotype 1b Hepatitis C Virus Evaluated by Bioinformatics Analysis.
    Uchida Y; Nakamura S; Kouyama JI; Naiki K; Motoya D; Sugawara K; Inao M; Imai Y; Nakayama N; Tomiya T; Hedskog C; Brainard D; Mo H; Mochida S
    Sci Rep; 2018 Jun; 8(1):8818. PubMed ID: 29892096
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of nucleotide polymerase inhibitor sofosbuvir plus the NS5A inhibitor ledipasvir or the NS5B non-nucleoside inhibitor GS-9669 against HCV genotype 1 infection.
    Gane EJ; Stedman CA; Hyland RH; Ding X; Svarovskaia E; Subramanian GM; Symonds WT; McHutchison JG; Pang PS
    Gastroenterology; 2014 Mar; 146(3):736-743.e1. PubMed ID: 24262278
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical and in vitro resistance to GS-9669, a thumb site II nonnucleoside inhibitor of the hepatitis C virus NS5B polymerase.
    Dvory-Sobol H; Voitenleitner C; Mabery E; Skurnac T; Lawitz EJ; McHutchison J; Svarovskaia ES; Delaney W; Miller MD; Mo H
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6599-606. PubMed ID: 25155588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of sofosbuvir resistance-associated variants in Brazilian and worldwide NS5B sequences of genotype-1 HCV.
    Peres-da-Silva A; Brandão-Mello CE; Lampe E
    Antivir Ther; 2017; 22(5):447-451. PubMed ID: 28085003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification of NS5B resistance against SOFOSBUVIR in hepatitis C virus genotype 3a, naive and treated patients.
    Younas S; Sumrin A; Hussain N; Bilal M
    J Appl Microbiol; 2022 Nov; 133(5):2826-2834. PubMed ID: 35916643
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Post-treatment resistance analysis of hepatitis C virus from phase II and III clinical trials of ledipasvir/sofosbuvir.
    Wyles D; Dvory-Sobol H; Svarovskaia ES; Doehle BP; Martin R; Afdhal NH; Kowdley KV; Lawitz E; Brainard DM; Miller MD; Mo H; Gane EJ
    J Hepatol; 2017 Apr; 66(4):703-710. PubMed ID: 27923693
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonstructural protein 5A resistance profile in patients with chronic hepatitis C treated with ledipasvir-containing regimens without sofosbuvir.
    Kitrinos KM; Corsa AC; Worth A; Hedskog C; Brainard DM; Miller MD; Mo H
    J Viral Hepat; 2018 Feb; 25(2):126-133. PubMed ID: 28833932
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of a novel replication-competent hepatitis C virus variant that confers the sofosbuvir resistance.
    Leumi S; Guo M; Lu J; Wang Z; Gan T; Han L; Ngari J; Tong Y; Xiang X; Xie Q; Wang L; Zhong J
    Antiviral Res; 2022 Jan; 197():105224. PubMed ID: 34864126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.